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 Established Facts: 3-M syndrome is a growth disorder presenting with severe pre- 
and post-natal growth retardation and is caused by mutations in three genes (CUL7, 
2 
 
OBSL1, and CCDC8).  
 Novel Insights: We describe two siblings with quite mild short stature who carry a 
homozygous pathogenic mutation in CCDC8causative of 3-M syndrome. This is the 
mildest case of 3-M syndrome reported to date and demonstrates the utility of 
genomic screening in children with undiagnosed growth disorders, especially from 
consanguineous families.  
 
Abstract 
Background: Short stature can be caused by mutations in a multitude of different genes. 3-M 
syndrome is a rare growth disorder marked by severe pre- and post-natal growth retardation 
along with subtle dysmorphic features. There have only been two prior reports of mutations 
in CCDC8 causing 3-M syndrome.  
Methods: Two patients presenting with mild short stature underwent whole exome 
sequencing. The mutation was confirmed via Sanger sequencing. We compare the clinical 
characteristics of our two patients to patients previously reported with mutations in the same 
gene.  
Results: Exome sequencing identified a homozygous frameshift mutation in CCDC8 in both 
patients. They presented with a much milder phenotype than previously described patients 
with the same mutation.  
Conclusion: In this study, we report a case of two sisters with relatively mild short stature 
who were found via exome sequencing to carry a previously reported homozygous mutation 
in CCDC8. These patients expand the anthropometric phenotype of 3-M syndrome and 
demonstrate the power of exome sequencing in the diagnosis of children with short stature. 
3-M syndrome should be considered in children with mild skeletal abnormalities, 
normal/high GH-IGF axis parameters and normal intelligence.  
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Introduction 
 
3-M syndrome (MIM 273750, 612921 and 614205) was first recognized by Miller, 
McMusick and Malvaux in 1975, who described a rare autosomal recessive primordial 
dwarfism characterized by severe prenatal and postnatal growth retardation but with normal 
mental development [1]. Approximately 100 cases have been reported in the literature since 
1975 [2]. Children are characteristically born extremely small for gestational age (SGA) and 
achieve a final height 5-6 SDS below the mean. Clinical characteristics include distinctive 
facial dysmorphism such as a triangular face, frontal bossing, midfacial hypoplasia, fleshy 
tipped nose, and full fleshy lips. Characteristic radiologic findings include slender long bones 
with diaphyseal constriction and flared metaphyses, tall vertebral bodies, anterior wedging of 
thoracic vertebral bodies, irregular upper and lower endplates, thoracic kyphoscoliosis, spina 
bifida occulta, small pelvic bones, small iliac wings, broad thorax with slender and horizontal 
ribs, and slightly delayed bone age. Prominent heels are most easily recognized in affected 
younger children. While the gonadal status of female patients with 3-M syndrome appears to 
be normal, male patients can develop gonadal failure with small testicular volumes, elevated 
gonadotropin concentrations, and sub- or infertility [3-4]. From an endocrine perspective, 
serum GH concentrations are usually normal and IGF-I concentrations are normal or low 
while response to growth hormone therapy is variable but typically poor [5].  
 
3-M syndrome is a genetically heterogeneous condition with three causal genes currently 
identified. In 2005, autozygosity mapping revealed a 3-M syndrome locus on chromosome 
6p21.1, and pathogenic mutations in CULLIN7 (CUL7 [MIM609577]) were subsequently 
identified as the primary cause of 3-M syndrome [6]. A previous study showed that CUL7 
accounts for approximately 84% of cases of 3-M syndrome (52/62) [7]. CUL7 is a major 
structural component of E3 ubiquitin ligase, which is involved in the proteasomal degradation 
pathway targeting p53 and the IGF-1/insulin signaling molecule IRS-1[8]. In 2009, mutations 
in Obscurin-like 1 (OBSL1 [MIM 610991]) were found as the second most common cause of 
3-M syndrome [9]. OBSL1 encodes a cytoskeletal adaptor protein which has been shown to 
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physically interact with CUL7, and loss-of-function mutations in OBSL1 lead to decreased 
levels of CUL7 [9]. A third 3-M causal gene was identified in 2011, in which 6 patients from 5 
families carried truncating mutations in CCDC8, four of whom carried the same frameshift 
mutation p.K205EfsX59 [10]. In co-expression studies, CCDC8 was shown to directly interact 
with OBSL1 but not CUL7 [10]. However, similar to CUL7, CCDC8 acts as a co-factor for 
p53-induced apoptotic processes [8]. To date, there has only been one additional report of a 
single family with a mutation in CCDC8[11], and thus, the full clinical spectrum of patients 
with mutations in this gene is yet to be elucidated.  
There are a multitude of genetic causes of short stature [12], many of which can be difficult to 
diagnose due to the subtlety of the associated clinical features. Next generation sequencing 
provides the opportunity to rapidly assess many genes and even the entire exome, facilitating 
the diagnosis of rare genetic conditions [13]. Herein, we report a case of two sisters who 
lacked an obvious syndromic cause for their relatively mild short stature, and, via exome 
sequencing, were found to carry the previously reported homozygous p.K205EfsX59 
mutation in CCDC8. These patients have the mildest degree of short stature associated with 
3-M syndrome to date and demonstrate the power of exome sequencing in the diagnosis of 
children with short stature. 
Case Report: 
Subject 1: 
Subject 1 was born at 37 weeks’ gestation with a pregnancy complicated by intrauterine 
growth restriction, with a birthweight of 2.72 kg (-1.4 SDS). Her antenatal and postnatal 
course was otherwise unremarkable and she was completely weaned from breastfeeding at 
one year of age. Her growth remained below the 3rd percentile throughout childhood (Figure 
1A). Further investigations performed indicated a normal karyotype, coeliac screen, thyroid 
function tests, plasma amino acids, immunoglobulins, and faecal elastase. Her appetite 
appeared normal throughout this period, and there were no developmental concerns.  
 
The subject is of Pakistani descent. Family history was significant for parental consanguinity. 
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Her maternal great-grandfather and paternal grandfather were brothers. Her younger sister 
was also referred to the paediatric endocrinology team for concerns regarding her growth, but 
she has two older brothers of normal height (188 cm and 175 cm). Her father is 180 cm and 
mother is 170 cm giving her a mid-parental target height of 168cm (75th-90th percentile).  
 
Examination revealed proportionate short stature, mild clinodactyly, mild frontal bossing and 
depression of her nasal bridge. After the molecular diagnosis was made via exome 
sequencing (see below), a closer examination indicated a triangular face, exaggerated lumbar 
lordosis, upturned nares, fleshy nose and lips, and prominent heels, which, although mild in 
presentation, could, together with her skeletal survey findings and family history, be 
suggestive of 3-M syndrome. IGF-1 and IGFBP-3 concentrations were normal [119 ng/ml, 
(-0.8 SDS, normal range 49-283) and 2.3 mg/l (-0.6 SDS, normal range 1.0-4.7) respectively]. 
Height velocity remained normal throughout childhood. A skeletal survey revealed gracile 
long bones and ribs, pectus excavatum and spina bifida occulta with a vertebral ossification 
defect in L4-5 but normal vertebral height (Figure 2).  
 
At the age of 11 years, Subject 1 started puberty with Tanner stage 2 breast development. A 
glucagon stimulation test was performed at this point due to her slightly suboptimal height 
velocity of 4.2 cm/year, but this revealed a normal GH peak of 15.2 ng/ml and a normal 
cortisol peak of 1070 nmol/l. The rest of her pituitary function screen was normal (free T4 
15.3 pmol/l (normal range 10.8-19.0), TSH 1.4 mU/l (normal range <6.0), LH <0.2 U/l, FSH 
0.3 U/l, oestradiol <44 pmol/l, PRL 115 mU/l). Height at last follow-up (11.9 years) was 
134.6 cm (-2.2 SDS), with a weight of 34.5 kg (-1.0 SDS), BMI 19.0 kg/m2 (+0.4 SDS), and 
head circumference of 53.2 cm (-0.35 SDS). 
 
Subject 2: 
Subject 2, Subject 1’s younger sister was born at 36 weeks’ gestation with a pregnancy 
complicated by intrauterine growth restriction, with a birthweight of 2.27 kg (-2.6 SDS). She 
was noted to feed poorly and exhibited poor weight gain, only reaching 6.6 kg (-4.9 SDS) at 
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1.3 years of life when she was referred to paediatric endocrinology. Early clinical 
examination revealed frontal bossing and midfacial hypoplasia. Investigations indicated a 
normal karyotype, celiac screen, and thyroid function tests. IGF-1 and IGFBP-3 
concentrations were normal [111 ng/ml (-1.0 SDS, normal range 51-303) and 2.6 mg/l (+0.3 
SDS, normal range 0.8-3.9) respectively]. Height velocity remained normal throughout 
childhood (Figure 1B). 
 
Further examination performed at 5.7 years of age revealed similar features to her sister, with 
upturned nares, fleshy nose and lips, long palpebral fissures and prominent heels. Repeat 
endocrine biochemistry was performed at 9.1 years due to a deceleration in height velocity 
but these investigations were all normal (IGF-1 111 ng/ml (-1.7 SDS, normal range 88-452), 
IGFBP-3 3.9 mg/l (-0.7 SDS, normal range 2.1-7.7), free T4 15.6 pmol/l (normal range 
10.8-19.0), TSH 2.6 mU/l (normal <6.0), LH <0.2 U/l, FSH 0.3 U/l, PRL 92 mU/l). A 
glucagon stimulation test demonstrated a normal GH peak of 29 ng/ml and a cortisol peak of 
1286 nmol/l. Height at last follow-up (10.2 years) was 121.8 cm (-2.7 SDS), weight 21.3 kg 
(-2.9 SDS), BMI 14.4 kg/m2 (-1.5 SDS), and head circumference 51.2 cm (-1.0 SDS). 
 
Molecular analysis 
Ethical approval for the protocol was granted by the Cincinnati Children’s Hospital Medical 
Center Institutional Review Board. Written informed consent was obtained from the subjects 
and their parents. Both subjects underwent whole exome sequencing at Cincinnati Children’s 
Hospital Medical Center using previously described methods [14]. Given the known 
consanguinity and two affected siblings with unaffected parents, we hypothesized that the 
causal variant would be a rare homozygous non-synonymous variant present in both subjects. 
We excluded all variants present with a minor allele frequency greater than 0.001 in the 1000 
Genomes database (www.1000genomes.org), the Exome Aggregation Consortium browser 
(http://exac.broadinstitute.org), or our internal variant database. Only a single variant met 
these criteria, the homozygous p.K205EfsX59 mutation in CCDC8. We then confirmed this 
mutation via Sanger sequencing (Figure 3). PCR primers are available on request.  
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Discussion 
To date, there have only been two reports describing a total of nine patients in six families 
carrying CCDC8 mutations causing 3-M syndrome, and only 3 mutations were identified[10,11]. 
The typical description of 3-M syndrome includes severe prenatal (usual birth weight SD 
scores < -3SD) and postnatal growth retardation (adult height in the range of -8 to -4 SD) 
although the birth weight can fall within the lower part of the normal range [8]. Interestingly, 
patients with mutations in CCDC8 (i.e. 3-M syndrome type 3, MIM 614205) tend to have a 
milder phenotype with a mean height at presentation of -4.4 SD (Table 1). In this report, we 
describe two patients with a previously described homozygous frameshift mutation in 
CCDC8 who present with a considerably milder phenotype than previously described (Table 
1). Their current height SDS scores of -2.2 and -2.7 fall within the relatively mild-moderate 
short stature range and, notably, Subject 1 had a normal birth weight, thus lacking prenatal 
growth retardation. Unfortunately, birth length data were unavailable for these patients so it is 
possible that Subject 1 was small for gestational age based on length criteria. Notably, their 
parents were rather tall with a mid-parental target height of +1 SD, thus, their actual degree of 
growth failure is more significant when this is taken into account. This highlights the 
importance in considering the deviation from target height when assessing a patient’s degree 
of short stature. Both subjects had normal head circumferences as is observed in 3-M 
syndrome. In retrospect, both subjects do exhibit mild features seen in 3-M syndrome 
including a slightly exaggerated lumbar lordosis, pectus excavatum and hypermobile finger 
joints, but these are relatively non-specific and did not raise suspicion for this rare diagnosis. 
The fleshy heels, a distinct finding in 3-M syndrome, became less prominent with time. 
Similarly, the radiological features were quite subtle and were not fully appreciated until after 
the molecular diagnosis was obtained.  
 
It is interesting to note that both subjects had elevated peak growth hormone and normal 
cortisol concentrations during a glucagon stimulation test. Additionally, they had normal 
IGF-1 levels. Taken together, the relatively robust growth hormone levels with normal IGF-1 
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levels may suggest a degree of growth hormone and possibly IGF-1 resistance, as has been 
previously described in 3-M syndrome [5]. In other cases reported in the literature, two 
patients with 3-M syndrome have been shown to have complete or partial growth hormone 
deficiency, although the majority have a normal growth hormone axis on testing [5, 15-17]. The 
rest of their pituitary function (TSH, LH, FSH, and PRL) screening was normal. 
 
These two girls are older than the CCDC8 deficient patients reported in the previous study, 
and the elder sister has started puberty with no evidence of gonadal failure. Gonadal status of 
female patients with 3-M syndrome has previously been reported to be normal, while males 
may have hypergonadotropic hypogonadism. It is not clear whether mutations in CCDC8 
affect gonadal status or if this is only the case in individuals with CUL7 mutations. Further 
follow-up of these patients is needed. 
 
In conclusion, we report a case of two siblings carrying a previously reported homozygous 
frameshift mutation in CCDC8 with mild short stature, one of whom had a normal birth 
weight, thus representing the mildest presentation of 3-M syndrome to date. An explanation 
for the same mutation causing highly variable clinical presentations remains to be fully 
elucidated, although it is important to consider the distance from the mid-parental target 
height when quantifying the degree of growth failure. 3-M syndrome should be considered in 
children with mild skeletal abnormalities, normal/high GH-IGF axis parameters and normal 
intelligence. We highlight the power of exome sequencing in children with short stature, 
which provides comprehensive genetic evaluation for patients who lack obvious specific 
molecular aetiologies.  
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Table 1. Clinical characteristics of the two affected subjects compared to patients previously 
reported with CCDC8 mutations 
Characteristic Previous reported 
patients with 
CCDC8 mutation 
(n=6) [10-11] 
Subject 1 Subject 2 
Birth weight  Range -2.2 to -6.3 
SDS 
Mean -3.4 SDS 
2720 grams (-1.4 
SDS) 
2270 grams (-2.6 SDS) 
Postnatal 
Growth 
(height) 
Range -3 to -6.7 SDS 
Mean -4.4 SDS 
134.6 cm  
(-2.2 SDS, 11.9 
years) 
121.8 cm 
(-2.7 SDS, 10.2 years) 
Postnatal 
Growth 
(weight) 
Range -3 to -5.2 SDS 
Mean -3.8 SDS 
34.5 kg 
(-1.0 SDS, 11.9 
years) 
21.3kg 
(-2.9 SDS, 10.2 years) 
Head 
Circumference  
4 out of 6 subjects 
with recorded HC 
were normal 
53.2 cm (-0.35 SDS, 
11.9 years) 
51.2 cm (-1.0 SDS, 
10.2 years) 
Skeletal 
Survey  
Tall vertebral bodies 
(5/9), slender long 
bones (5/9), short 
thorax (6/6) 
Gracile long bones 
and ribs, pectus 
excavatum and spina 
bifida occulta with a 
vertebral ossification 
defect in L4-5 but 
normal vertebral 
height 
Slightly exaggerated 
lumbar lordosis, pectus 
excavatum 
Facial 
Features 
Triangular face (7/9), 
fleshy tipped nose 
(9/9), frontal bossing 
(8/9), pointed chin 
(7/9),  midface 
hypoplasia (6/9), 
long philtrum (1/6) 
Triangular face, mild 
clinodactyly, 
upturned nares, 
fleshy nose and lips, 
mild frontal bossing 
and depression of her 
nasal bridge 
Frontal bossing and 
midfacial hypoplasia, 
upturned nares, fleshy 
nose and lips, long 
palpebral fissures 
Other 
Distinguishing 
Features 
Prominent fleshy 
heels (6/9) and 
hypermobility of 
joints (2/9) 
Fleshy heels and 
hypermobile finger 
joints 
Fleshy heels and 
hypermobile finger 
joints 
Puberty  NA Tanner stage 2 breast 
development (11.9 
years) 
Pre-pubertal (10.2 
years) 
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Figure 1: Growth charts of the two subjects. A. Subject 1. B. Subject 2.  
Figure 2: Skeletal survey images of Subject 1 demonstrating (a) gracile ribs with evidence of 
pectus excavatum (oblique anterior rib angles and relatively horizontal posterior ribs), and (b-c) 
gracile long bones in the upper limb. The left humerus (b) is also bowed with slight expansion 
of the diaphysis. Similar long bone appearances were observed in the lower limbs (not shown). 
Figure 3: Chromatograms showing a homozygous insertion of a guanine nucleotide in the 
two subjects.  
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